Study estimates 12-month kidney stone incidence in the US at 2.1%

YOLT-203 is currently being assessed in the early phase 1 YOLT-203-101 trial.

“The prevalence of kidney stones has increased over 80% over the last 30 years, and the epidemiology has changed such that it's beginning at a younger age now,” says Gregory Tasian, MD, MSc, MSCE.

“What this means for patients is that thiazides remain an important option in the toolkit for preventing kidney stone recurrence,” says Ryan S. Hsi, MD, FACS.

“You have tradeoffs with every device that you use,” says Amy E. Krambeck, MD.

Any stone fragmentation was achieved in 88% of patients.

"The great news is that we have now completed recruitment. We actually recruited more than 1700 patients," says Kari A.O. Tikkinen, MD, PhD.